Research and Clinical Trials

GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
Brief Description  
To determine if post-operative chemotherapy and radiation can significantly improve recurrence (cancer coming back)-free survival when compared to radiation therapy alone in Stage I-IIA cervical cancer patients with intermediate risk factors after treatment with radical hysterectomy (removal of the uterus and part of the vagina) and lymph node removal.
Who may be Eligible  
Key inclusion criteria: Subjects must have stage I-IIA cervical cancer treated with radical hysterectomy and lymph node removal; Subjects must have intermediate risk factors as determined by the surgeon; Subjects must have adequate blood counts and kidney and liver function; Subjects must have had surgery at least 3 weeks prior to but not more than 8 weeks prior to study entry; Key exclusion criteria: Subjects with severe infection; Subjects with a blockage or bleeding in the bowel; Subjects who have already received treatment for cervical cancer; Subjects with a history of a previous cancer (unless there has been no evidence of the cancer for at least 5 years or if it was non-melanoma skin cancer).
Gynecological Cancer
IRB Number  
Principal Investigator  
Higgins, Robert

For More Information, Contact  Sarah  L, Norek
Phone:  (704) 355-1520  Fax:  (704) 355-1188  
Address:Blumenthal Cancer Center 1025 Morehead Medical Drive Suite 600 Charlotte, NC 28204